The largest database of trusted experimental protocols

14 protocols using cannabidiol

1

CBD Effects on Neuronal Activity

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cannabidiol (2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) was obtained from Tocris Bioscience (Bio-Techne, Abingdon, United Kingdom). AM281 (CB1 receptor antagonist; 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-4-morpholinyl-1H-pyrazole-3-carboxamide) and AM630 (CB2 receptor antagonist; 6-iodo-2-methyl-1-(2-morpholin-4-ylethyl)indol-3-yl]-(4-methoxyphenyl)methanone) were obtained from Cayman Chemicals (Ann Arbor, MI). SB-366791 (N-(3-methoxyphenyl)-4-chlorocinnamide), rhodamine 6G, cremophor, dimethyl sulphoxide (DMSO), urethane, and MIA were obtained from Sigma-Aldrich (St. Louis, MO). Solutions of CBD, AM281, AM630, and SB-366791 were prepared in vehicle (1:1:18; DMSO:cremophor:saline) on the day of use. rhodamine 6G (0.05%) and MIA were dissolved in saline. Physiological buffer (135 mM NaCl, 20 mM NaHCO3, 5 mM KCl, 1 mM MgSO4*7H2O, pH = 7.4) was prepared in the laboratory.
+ Open protocol
+ Expand
2

CBD, THC, and Tranilast Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cannabidiol (CBD) was purchased from Tocris Cookson (Bristol, UK). Tissue culture reagents were purchased from Gibco-BRL (San Giuliano Milanese, MI, Italy) and Sigma (St. Louis, MO, USA). Δ9-tetrahydrocannabinol (THC) and tranilast (TNL) were purchased from Sigma. The authorization number for the scientific use of THC was n. SP/94, of 07.07.2021.
+ Open protocol
+ Expand
3

CBD and Doxorubicin Combination Treatment

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cannabidiol was obtained from Tocris Bioscience (Bristol, UK). CBD was initially dissolved in DMSO (stock concentration of 75 mM) with subsequent dilutions in serum-free tissue culture medium for in vitro experiments. Doxorubicin hydrochloride was purchased from Abcam (Cambridge, UK) and the stock dilution in DMSO to 25 mM was diluted in serum-free medium. The following antibodies were purchased from Cell Signaling Technology [New England Biolabs (NEB), Hertfordshire, UK]: PathScan® Multiplex Western Cocktail I (#5301), anti-Phospho-mTOR (Ser2448) (D9C2) XP® Rabbit mAb (#5536), β-Actin (8H10D10) Mouse mAb (#3700), anti-Rabbit IgG, HRP-linked Antibody (#7074) and anti-Mouse IgG, HRP-linked Antibody (#7076). Concanavalin A was from Sigma–Aldrich, UK (#C2272) with stock solutions stored at 5 mg/mL in dH2O.
+ Open protocol
+ Expand
4

Isolation and Treatment of Glial Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Primary microglia and astrocytes were isolated and cultured from C57BL/6J and CX3CR1GFP/wt [51 (link),52 (link)] mice as described before [53 (link),54 (link)]. After 10–14 days microglial cells were isolated from astrocytic monolayer and used for further experiments. A375 [55 (link)] (gifted by Simon Jasinski-Bergner, University Halle-Wittenberg, Halle (Saale), Germany), BV2 microglia [56 (link)] (obtained from Ullrich, University of Zürich, Zürich, Switzerland) and primary glial cells were cultured in DMEM (Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS (Invitrogen) and 1% penicillin/streptomycin (Invitrogen). LN229 [57 (link)] were cultured in RPMI medium (Lonza, Basel, Switzerland) with 10% FBS and 1% penicillin/streptomycin. After two days, the medium was collected from confluent astrocytes or BV2 microglia, filtered (Sarstedt, Nümbrecht, Germany), and applied on the tumor cells in a 1:1 ratio with the respective culture medium. This medium was added 3 h before starting the imaging for both single cell and collective migration experiments.
For cannabinoid treatment cannabidiol (5 µM, Tocris Bioscience, Bristol, UK) [39 (link),58 (link),59 (link)], tetrahydrocannabinol (5 µM, Tocris) [42 (link)] or a combination of both was applied 3 h before the start of the experiments. THC and CBD were both dissolved in DMSO.
+ Open protocol
+ Expand
5

Cannabidiol Intracerebral Microinjection Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cannabidiol (Tocris, UK) was dissolved in a mixture of dimethylsulfoxide (DMSO; 10%) and phosphate buffer solution (PBS, 90%) (Shirazi-zand, Ahmad-Molaei, Motamedi, & Naderi, 2013 (link)). Microinjection of Cannabidiol into right lateral ventricle was in a volume of 2 μL. ICV injection of Cannabidiol at doses of 50, 100, and 200 ng/rat (Shirazi-zand et al., 2013 (link)) was given by inserting a 30-gauge injection cannula 1 mm beyond the tip of the guide cannula to the site of injection. The injection cannula was connected with a polyethylene tube to a Hamilton syringe. Injection (1μL) was done over 60s. As, Cannabidiol was injected in the treatment groups, the vehicle group received DMSO 10% through ICV injection. Analysis between control and vehicle groups was done because there are evidences about possible neuroprotective role of vehicle (dimethylsulfoxide) (Di Giorgio et al., 2008 (link)).
+ Open protocol
+ Expand
6

Cannabinoid Receptor Ligand Procurement

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cannabidiol (2-((1S,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-2-enyl)-5-pentylbenzene-1,3-diol), and HU 210 ((6aR)-trans-3-(1,1-dimethylheptyl)-6a,7,10,0a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b.d]pyran-9-methanol) were obtained from Tocris Cookson (Bristol, UK). Anandamide (N-(2-hydroxyethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide), and HU 211 (3-(1,1-dimethylheptyl)-6aS,7,10,10aS- tetrahydro-1-hydroxy-6,6-dimethyl-6H- dibenzo[b,d]pyran-9-methanol; dexanabinol) were purchased from Cayman Chemical Co. (Ann Arbor, MI, USA). DMSO (dimethyl sulfoxide) were obtained from Sigma-Aldrich Sweden AB (Stockholm, Sweden). Alcohol prep pads (70% isopropyl alcohol) and saline were from Apoteket AB (Umeå, Sweden).
+ Open protocol
+ Expand
7

Preparation of Cytotoxic Drug Solutions

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cisplatin (CDDP—Sigma-Aldrich) was dissolved in phosphate buffered saline (PBS) with Ca2+ and Mg2+. Mitoxantrone (MTX—Sigma-Aldrich) was dissolved in DMSO as stock solutions. The cannabidiol (CBD—Tocris, Bristol, UK) was dissolved in ethanol as stock solutions in concentration of 5 mg/mL. The drugs were dissolved to the respective concentrations with culture medium before use.
+ Open protocol
+ Expand
8

Cannabidiol Oocyte Treatment Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
First, 10 mM cannabidiol (CBD; Tocris, Bristol, UK) stocks were prepared and were stored at −20 °C. Directly before the CBD treatment for oocytes started, stocks were diluted with oocyte Ringer (ORi) to result in concentrations of 20 μM and 40 μM.
+ Open protocol
+ Expand
9

Synthesis and Use of Cannabinoids

Check if the same lab product or an alternative is used in the 5 most similar protocols
GAT211, GAT228, and GAT229 were synthesized and provided by the laboratory of Dr. Ganesh Thakur (Northeastern University). 2-AG, AEA, (−)-cis-3-[2-Hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol (CP55,940), THC, and cannabidiol (CBD) were purchased from Tocris Bioscience (Bristol, UK). Cannabinoids were dissolved in DMSO (final concentration of 0.1% in assay media for all assays) and added directly to the media at the concentrations and times indicated. No effects of vehicle were observed compared to assay media alone.
+ Open protocol
+ Expand
10

Neuroprotective Compound Screening in PCD Model

Check if the same lab product or an alternative is used in the 5 most similar protocols
Approaches 1 and 2 (Figure 1B): To evaluate the neuroprotective potential of compounds that modulate calcium‐sensitive mitochondrial‐associated signalling, we co‐applied the compounds with anti‐Yo/rCDR immediately at PCD onset (approach 1) or 4 days after PCD induction (approach 2); cultures were treated for 6 days. Compounds tested were AM281 [IC50: 12 nM (CB1R), 4.2 μM (CB2R); #1115, Tocris Bioscience, Bristol, UK], benzamil [IC50: approximately 100 nM (NCX); #3380; Tocris], butylated hydroxytoluene [BHT; IC50: 3.5 μM (ROS); #W218405; Sigma], cannabidiol [CBD; IC50: 3.35 μM (CB1R), 27.5 μM (CB2R); #1570; Tocris], CGP37157 [IC50: 400 nM (NCX); #1114; Tocris], cyclosporin‐A [CsA; IC50: 5 nM (MPTP); #1101; Tocris] and KB‐R7943 [IC50: 700 nM (NCXrev), 5.5 μM (MCU); #1244; Tocris]. As this PCD model system is based on an interface hydrophilic PTFE membrane‐diffusion approach where the cOTSC is not submerged, the system behaves like an in vivo brain. Therefore, several test dosages were evaluated starting with 2.5‐fold of the IC50 value to determine effective, nontoxic doses if there was no literature guided initial dose selection available for this kind of culture system. Depending on the hydrophilic or hydrophobic nature of the used compounds, the effective dosage was determined between 2.5 to 200 times of the IC50 value.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!